Ronald Gelbman has a longstanding career in the pharmaceutical industry, where he has made significant contributions. Born in 1948, he became the Interim CEO of Haemonetics Corporation on September 30, 2015, stepping in after the previous CEO left to pursue...

Ronald Gelbman has a longstanding career in the pharmaceutical industry, where he has made significant contributions. Born in 1948, he became the Interim CEO of Haemonetics Corporation on September 30, 2015, stepping in after the previous CEO left to pursue other opportunities. Gelbman has been a member of Haemonetics' Board of Directors since 2000 and served as their Interim CEO for a short period until May 2016, balancing his executive responsibilities while remaining an influential board member. Before this role, he retired from Johnson & Johnson in 2000, where he held key positions, including Worldwide Chairman of the Pharmaceuticals, Diagnostics, and Health Systems Groups. His extensive experience at one of the world's largest healthcare companies sets a solid groundwork for his leadership style. Not only is he active in corporate governance, but he is also on several boards, including advisories for Cambryn Biologics and SunTrust Southwest Florida. Throughout his career, Gelbman demonstrated a commitment to aligning business strategies with innovative healthcare solutions.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Haemonetics CEOs

H

Ronald Gelbman

Ex-CEO of Haemonetics

Field of Expertise

Healthcare & Life Sciences - Pharmaceuticals

Sector of Economy

Healthcare

Born

January 1, 1948 - 77 years ago

CEO of Haemonetics for

0 years 1 month (Sep 2015 - Oct 2015)

Previous Experience

Retired from Johnson & Johnson after serving in senior executive roles including Worldwide Chairman of the Pharmaceuticals, Diagnostics and Health Systems Groups.

Rivals

Competitors/colleagues of Ronald Gelbman

D

Kevin Sayer

CEO of DexCom

2023 Compensation

Stock

$13.51M

Salary

$1.09M

Bonus

$1.99M

Other

$143.54K

Total Holdings

$26.30M

P

Adam Elsesser

CEO of Penumbra

2023 Compensation

Stock

$0.00

Salary

$600.00K

Bonus

$0.00

Other

$1.62K

Total Holdings

$244.34M

S

Laura A. Francis

CEO of SI-BONE, Inc.

2022 Compensation

Stock

$0.00

Salary

$604.00K

Bonus

$504.16K

Other

$0.00

Total Holdings

$9.76M

I

Michael Levitz

CEO of Insulet

2023 Compensation

Stock

$0.00

Salary

$842.31K

Bonus

$2.03M

Other

$9.90K

Total Holdings

$14.76M

Q

Masoud Toloue

CEO of Quanterix Corporation

2023 Compensation

Stock

$0.00

Salary

$600.00K

Bonus

$810.00K

Other

$9.90K

Total Holdings

$2.51M

D

Terry Gregg

CEO of DexCom

2023 Compensation

Stock

$12.49M

Salary

$1.09M

Bonus

$1.99M

Other

$143.54K

Total Holdings

$142.54M

Holdings

See how much did Ronald Gelbman make over time.

Ronald Gelbman has a rich history in the pharmaceutical sector, particularly through his long-standing relationship with Haemonetics Corporation. Although specific numbers about his holdings are not disclosed, his wealth was significantly tied to the company. He served as the Interim...

Ronald Gelbman has a rich history in the pharmaceutical sector, particularly through his long-standing relationship with Haemonetics Corporation. Although specific numbers about his holdings are not disclosed, his wealth was significantly tied to the company. He served as the Interim CEO, a position he held temporarily which usually does not come with stock grants or options. His decision to step into this role came during a critical transition for the company, and while in charge, he received a monthly salary of $67,500. Notably, his past position at Johnson & Johnson likely influenced stock values in his portfolio, detailing a career where he understood the nuances of market fluctuations and held a considerable stake in the firms he led.

Loading...

Insider Trading

See recent insider trades of Ronald Gelbman.

No insider trades found for this CEO.

Compensation History

See how much did Ronald Gelbman make over time.

In 2015, Ronald Gelbman's total compensation as interim CEO of Haemonetics was $398,769, which exclusively comprised his salary. He did not receive any bonuses, stock grants, or options, which is typical for an interim position. His lack of additional perks reflects the company's compensation philosophy, emphasizing performance and aligning with long-term shareholder interests. Although his salary was substantial, it is noteworthy that he didn’t gain extra from stock or other incentive plans during this brief period, indicating his focused role was more about stability than personal gain during a transitional phase for the company. This approach keeps in alignment with his past experiences at major firms like Johnson & Johnson, where executive pay often correlates strongly with performance metrics.

Year

2015

Total Compensation

$398.77K

Salary

$398.77K

Board Justification

The compensation philosophy emphasizes a pay-for-performance culture that aligns executive compensation with the long-term interests of shareholders.

Bonus

$0.00

Board Justification

Mr. Gelbman did not receive a bonus as he was serving in an interim role during a portion of fiscal 2016.

Other

$0.00

Board Justification

No additional compensation was reported for Mr. Gelbman outside of salary.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards were granted to Mr. Gelbman during his tenure as Interim CEO.

Performance Metrics

Performance metrics for executive compensation are based on achieving corporate financial goals, including revenue and operating income.

Other Haemonetics CEOs

Here are other CEOs of Haemonetics

Brian Concannon

Ex-CEO of Haemonetics

April 2009 - September 2015

Christopher Simon

CEO of Haemonetics

June 2016 - Present